Methods for nuclear reprogramming of cells

ABSTRACT

Described herein are methods for enhancing the nuclear reprogramming of somatic cells to become induced pluripotent stern cells. In particular, the methods disclosed herein involve the use of damage-associated molecular pattern molecules (DAMP). In certain embodiments the DAMPs are aluminum compositions such as aluminum hydroxide. Such DAMPs have unexpectedly and surprisingly been found to enhance the nuclear reprogramming efficiency of the reprogramming factors commonly used to induce somatic cells to become induced pluripotent stern cells. Accordingly, this disclosure describes methods of nuclear reprogramming as well as cells obtained from such methods along with therapeutic methods for using such cells for the treatment of disease amendable to treatment by stem cell therapy; as well as kits for such uses.

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 20, 2013, is named 0132-0004PRI_SL.txt and is 39,860 bytes in size.

FIELD OF THE INVENTION

The invention relates to stem cell reprograming methods.

BACKGROUND OF THE INVENTION

The transformation of differentiated cells to induced pluripotent stem cells (iPSCs) has revolutionized stern cell biology by providing a more tractable source of pluripotent cells for regenerative therapy. The derivation of iPSCs from numerous normal and diseased cell sources has enabled the generation of stem cells for eventual use in cell therapy and regenerative medicine.

Seminal studies by Yamanaka and colleagues revealed that ectopic expression of certain transcriptional factors could induce pluripotency in somatic cells. These induced pluripotent stem cells self-renew and differentiate into a wide variety of cell types, making them an appealing option for disease- and regenerative medicine therapies. They have been used to successfully model human disease and have great potential for use in drug screening and cell therapy. Furthermore, iPSCs generated from diseased cells can serve as useful tools for studying disease mechanisms and potential therapies. However, much remains to be understood about the underlying mechanisms of reprogramming of somatic cells to iPSCs, and there is concern regarding potential clinical applications in the absence of mechanistic insights.

The original set of factors (RFs) for reprogramming to pluripotency include Oct3/4, Sox2, c-Myc, Klf4, Lin28, and Nanog. Oct3/4 and Sox2 are transcription factors that maintain pluripotency in embryonic stem (ES) cells while Klf4 and c-Myc are transcription factors thought to boost iPSC generation efficiency. The transcription factor c-Myc is believed to modify chromatin structure to allow Oct3/4 and Sox2 to more efficiently access genes necessary for reprogramming while Klf4 enhances the activation of certain genes by Oct3/4 and Sox2. Nanog, like Oct3/4 and Sox2, is a transcription factor that maintains pluripotency in ES cells while Lin28 is an mRNA-binding protein thought to influence the translation or stability of specific mRNAs during differentiation. It has also been shown that retroviral expression of Oct3/4 and Sox2, together with co-administration of valproic acid, a chromatin destabilizer and histone deacetylase inhibitor, is sufficient to reprogram fibroblasts into iPSCs.

Several classes of vectors have been shown to induce pluripotency when overexpressing the requisite gene combinations. The earliest vectors relied on DNA-integrating retroviruses and transposons for nuclear reprogramming. While effective, they inherently raise concerns about potential tumorigenicity either by insertional mutagenesis or re-expression of oncogenic reprogramming factors. While Cre-LoxP site gene delivery or PiggyBac transposon approaches have been used to excise foreign DNA from the host genome following gene delivery, neither strategy eliminates the risk of mutagenesis because they leave a small insert of residual foreign DNA.

As an alternative to genetic modification, mRNA, episomal DNA plasmids, and cell permeant proteins (CPP) have been shown to be effective for reprogramming factors.

These non-integrating vectors, however functional, often result in reduced reprogramming efficiencies either as a result of their specific mechanism of action or because of the cumbersome nature of their practice. Because, non-integrating and/or small-molecule based approaches for iPSC generation or transdifferentiation to a different somatic cell type are clinically relevant vectors, it becomes important to increase the robustness, efficiency, and ease of use of such methods. The present invention addresses these issues.

SUMMARY OF THE INVENTION

One aspect of the invention relates to a method of nuclear reprogramming of a mammalian somatic cell, the method comprising: contacting a population of mammalian somatic cells with (a) an effective dose of a damage-associated molecular pattern (DAMP) molecules; and (b) a cocktail of reprogramming factors; for a period of time sufficient to reprogram the mammalian somatic cells to desired cell type of interest.

In one embodiment of this aspect of the invention, the DAMP is an aluminum composition. In another embodiment, the aluminum composition and cocktail of non-integrating reprogramming factors are provided simultaneously. In another embodiment, the aluminum composition and cocktail of non-integrating reprogramming factors are provided sequentially. In still a further embodiment, the aluminum composition is selected from the group consisting of aluminum hydroxide, aluminum phosphate and aluminum sulfate. In still another embodiment, the aluminum composition is aluminum hydroxide. In yet another embodiment, the aluminum hydroxide is present in a concentration of about or at least 40-80 micrograms/ml. In still a further embodiment, the effective dose of the aluminum hydroxide is at least or about 30-60 micrograms/ml. In yet another embodiment, the aluminum composition is aluminum phosphate. In still another embodiment, the aluminum composition is aluminum sulfate.

In a further embodiment, the mammalian somatic cells are human cells. In still a further embodiment, the cocktail of reprogramming factors comprises use of Oct4, Sox2, Lin28, and Nanog, and the cells are reprogrammed to pluripotency. In still another embodiment, the cocktail of reprogramming factors comprises the use of Oct4, Sox2, c-Myc, and Klf4, and the cells are reprogrammed to pluripotency. In still another embodiment, the somatic cell type is peripheral blood mononuclear cell (PBMC), cord blood mononuclear cells, or fibroblasts. In yet a further embodiment, the reprogramming factors are provided as cell permeant proteins. In a further embodiment, the reprogramming factors are provided as nucleic acids encoding reprogramming proteins. In yet another embodiment, the desired cell type of interest is an induced pluripotent stem (iPS) cell.

Another aspect of the invention involves a method of nuclear reprogramming wherein the nuclear reprogramming efficiency is greater than if the method was carried out without the aluminum composition. In one embodiment of this aspect of the invention, the nuclear reprogramming efficiency is about 1 to about 5 fold greater with respect to the expression of at least one key pluripotency marker. In another embodiment, the nuclear reprogramming efficiency is about 1 to about 5 fold greater with respect to the amount of desired cell type of interest produced.

Another aspect of the invention relates to a population of induced pluripotent stem cells produced by any of the methods of the disclosure. In one embodiment, the induced pluripotent stem cells are human cells.

Another aspect of the invention relates to a kit for practicing the methods of the invention. In one embodiment the kit comprises reprogramming factors and an aluminum composition. In another embodiment, the kit further comprises somatic cells. Yet a further aspect relates to a therapeutic composition comprising a DAMP composition, such as an aluminum composition, and one or more reprograming factors and/or nucleic acids encoding the same and/or small molecules, for administration in vivo, for therapeutic modulation of cell and/or tissue phenotype. Another aspect relates to methods of treating a patient in need thereof by administering to the patient a therapeutically effective amount of the therapeutic compositions of the disclosure.

BRIEF DESCRIPTION OF THE FIGURES

A more complete understanding of the present invention may be obtained by reference to the accompanying drawings, when considered in conjunction with the subsequent detailed description. The embodiments illustrated in the drawings are intended only to exemplify the invention and should not be construed as limiting the invention to the illustrated embodiments.

FIG. 1 shows an image of the process of obtaining iPSCs using methods described herein.

FIGS. 2, 3, 4 and 5 illustrate experimental results of using varying concentrations of aluminum hydroxide to obtain iPSCs from various donors under hypoxic and normoxic conditions using the methods disclosed herein.

DETAILED DESCRIPTION OF THE INVENTION

Described herein are methods for enhancing the nuclear reprogramming of somatic cells to become induced pluripotent stem cells. In particular, the methods disclosed herein involve the use of damage-associated molecular pattern molecules (DAMPs). In certain embodiments the DAMPs are aluminum compositions such as aluminum hydroxide. Such DAMPs have unexpectedly and surprisingly been found to enhance the nuclear reprogramming efficiency of the reprogramming factors commonly used to induce somatic cells to become induced pluripotent stem cells. Accordingly, this disclosure describes methods of nuclear reprogramming as well as cells obtained from such methods along with therapeutic methods for using such cells for the treatment of diseases amendable to treatment by stem cell therapy as well as kits for such uses.

It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, and reagents described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects. Typically the term is meant to encompass approximately or less than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% variability depending on the situation.

The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.”

As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve methods of the invention.

“Totipotency” is referred to herein as the ability of a single cell to divide and/or differentiate to produce all the differentiated cells in an organism, including extra-embryonic tissues. Totipotent cells include spores and zygotes. In some organisms, cells can dedifferentiate and regain totipotency.

“Pluripotency” is referred to herein as the potential to differentiate into any of the three germ layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), mesoderm (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and nervous system).

“Pluripotent stem cells” include natural pluripotent stem cells and induced pluripotent stem cells. They can give rise to any fetal or adult cell type. However, alone they generally cannot develop into a fetal or adult organism because they lack the potential to contribute to extra-embryonic tissue, such as the placenta.

“Induced pluripotent stem cells” or (“iPSCs”) are similar to natural pluripotent stem cells, such as embryonic stem (ES) cells, in many aspects, such as the expression of certain stem cell genes and/or proteins, chromatin methylation patterns, doubling time, embryoid body formation, teratoma formation, viable chimera formation, and potency and differentiability. Induced pluripotent cells may be derived from for example, adult stomach, liver, skin cells and blood cells. iPSCs may be derived by transfection of certain stem cell-associated genes into non-pluripotent cells, such as adult fibroblasts. In certain embodiments, transfection may be achieved through viral vectors, such as retroviruses, for example, and non-viral or episomal vectors. Transfected genes can include, but are not limited to, master transcriptional factors Oct-3/4 (Pou5f1), Klf4, c-myc, Sox2, Oct-4, Nanog and Lin28 transgenes). Sub-populations of transfected cells may begin to become morphologically and biochemically similar to pluripotent stem cells, and can be isolated through morphological selection, doubling time, or through a reporter gene and antibiotic selection.

“Key pluripotency markers” known by one of ordinary skill in the art include but are not limited to the gene and/or protein expression of alkaline phosphatase, SSEA3, SSEA4, Sox2, Oct3/4, Nanog, TRA160, TRA181, TDGF 1, Dnmt3b, FoxD3, GDF3, Cyp26al, TERT, and zfp42.

“Multipotency” is referred to herein as multipotent progenitor cells which have the potential to give rise to multiple cell types, but a number of lineages more limited than a pluripotent stem cell. For example, a multipotent stem cell is a hematopoietic cell that can develop into several types of blood cells, but cannot develop into brain cells or other types of cells.

“Reprogramming factors,” as used herein, refers to one or a cocktail of biologically active polypeptides (or nucleic acids, e.g., DNA or RNA, encoding them) or small molecules that act on a cell to alter transcription, and which upon expression, reprogram a somatic cell to a different cell type, or to multipotency or to pluripotency. In some embodiments, the reprogramming factors may be non-integrating, i.e., provided to the recipient somatic cell in a form that does not result in integration of exogenous DNA into the genome of the recipient cell.

In some embodiments the reprogramming factor is a transcription factor, including without limitation, Oct3/4; Sox2; Klf4; c-Myc; and Nanog. Also of interest as a reprogramming factor is Lin28, which is an mRNA-binding protein thought to influence the translation or stability of specific mRNAs during differentiation.

Reprogramming factors of interest also include factors useful in transdifferentiation, where a somatic cell is reprogrammed to a different somatic cell. For the purpose of transdifferentiation of one somatic cell to another, substantially different, somatic cell type, a different set of reprogramming factors finds use. For example, to transdifferentiate a fibroblast to a cardiomyocyte, one might use cell permeant peptides Gata4, Mef2c and Tbx5 (Leda et al., Cell, Volume 142, Issue 3, 375-386, 6 Aug. 2010, herein specifically incorporated by reference.)

The reprogramming factors may be provided as compositions of isolated polypeptides, i.e. in a cell-free form, which are biologically active or as a nucleic acids (e.g., DNA, RNA) encoding the same. Biological activity may be determined by specific DNA binding assays; or by determining the effectiveness of the factor in altering cellular transcription. A composition of the invention may provide one or more biologically active reprogramming factors. The composition may comprise at least about 50 μg/ml soluble reprogramming factor, at least about 100 μg/ml; at least about 150 at least about 200 μg/ml, at least about 250 μg/ml, at least about 300 μg/ml, or more.

A Klf4 polypeptide is a polypeptide comprising the amino acid sequence that is at least 70% identical to the amino acid sequence of human Klf4, i.e., Kruppel-Like Factor 4 the sequence of which may be found at GenBank Accession Nos. NP_004226 (SEQ ID NO: 1) and NM_004235 (SEQ ID NO: 2). Klf4 polypeptides, e.g. those that are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or 100% identical to the sequence provided in GenBank Accession No. NM_004235 (SEQ ID NO: 2), and the nucleic acids that encode them find use as a reprogramming factor in the present invention.

A c-Myc polypeptide is a polypeptide comprising an amino acid sequence that is at least 70% identical to the amino acid sequence of human c-Myc, i.e., myelocytomatosis viral oncogene homolog, the sequence of which may be found at GenBank Accession Nos. NP_002458 (SEQ ID NO: 3) and NM_002467 (SEQ ID NO: 4). c-Myc polypeptides, e.g. those that are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or 100% identical to the sequence provided in GenBank Accession No. NM_002467 (SEQ ID NO: 4), and the nucleic acids that encode them find use as a reprogramming factor in the present invention.

A Nanog polypeptide is a polypeptide comprising an amino acid sequence that is at least 70% identical to the amino acid sequence of human Nanog, i.e., Nanog homeobox, the sequence of which may be found at GenBank Accession Nos. NP_079141 (SEQ ID NO: 5) and NM_024865 (SEQ ID NO: 6). Nanog polypeptides, e.g. those that are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or 100% identical to the sequence provided in GenBank Accession No. NM_024865 (SEQ ID NO: 6), and the nucleic acids that encode them find use as a reprogramming factor in the present invention.

A Lin-28 polypeptide is a polypeptide comprising an amino acid sequence that is at least 70% identical to the amino acid sequence of human Lin-28, i.e., Lin-28 homolog of C. elegans, the sequence of which may be found at GenBank Accession Nos. NP_078950 (SEQ ID NO: 7) and NM_024674 (SEQ ID NO: 8). Lin-28 polypeptides, e.g. those that are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or 100% identical to the sequence provided in GenBank Accession No. NM_024674 (SEQ ID NO: 8), and the nucleic acids that encode them find use as a reprogramming factor in the present invention.

An Oct3/4 polypeptide is a polypeptide comprising an amino acid sequence that is at least 70% identical to the amino acid sequence of human Oct3/4, also known as Homo sapiens POU class 5 homeobox 1 (POU5F1) the sequence of which may be found at GenBank Accession Nos. NP_002692 (SEQ ID NO: 9) and NMP_002701 (SEQ ID NO: 10). Oct3/4 polypeptides, e.g. those that are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or 100% identical to the sequence provided in GenBank Accession No. NM_002701 (SEQ ID NO: 10), and the nucleic acids that encode them find use as a reprogramming factor in the present invention.

A Sox2 polypeptide is a polypeptide comprising the amino acid sequence at least 70% identical to the amino acid sequence of human Sox2, i.e., sex-determining region Y-box 2 protein, the sequence of which may be found at GenBank Accession Nos. NP_003097 (SEQ ID NO: 11) and NM_003106 (SEQ ID NO: 12). Sox2 polypeptides, e.g. those that are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or 100% identical to the sequence provided in GenBank Accession No. NM_003106 (SEQ ID NO: 12), and the nucleic acids that encode them find use as a reprogramming factor in the present invention.

Small molecules, including without limitation valproic acid, hydroxamic acid, trichostatin A, suberoylanilide hydroxamic acid, BIX-01294 and BayK8644 have been described as useful in reprogramming cells (see Shi et al. (2008) Cell Stem Cell 6; 3(5):568-574 and Huangfu et al. (2008) Nature Biotechnology 26:795-797, each herein specifically incorporated by reference).

“Damage-associated molecular pattern molecules” (DAMPs) also known as danger-associated molecular pattern molecules, as used herein are molecules that can initiate and perpetuate immune responses in a noninfectious inflammatory response. In contrast, Pathogen-associated molecular pattern molecules (PAMPs) initiate and perpetuate the infectious pathogen inflammatory response. DAMPs may be nuclear or cytosolic proteins. When released outside the cell or exposed on the surface of the cell following tissue injury, they may move from a reducing to an oxidizing milieu, which can result in their denaturation. Following necrosis, tumor DNA is released outside the nucleus, and outside the cell, which may become a DAMP. Examples of DAMPs can include but are not limited to HMGB1, DNA, RNA, S100 molecules, purine metabolites, uric acid, nanoparticles, asbestos, aluminum compositions such as aluminum salts, beta-amyloid, silica, cholesterol crystals, hemozoin, calcium pyrophosphate dehydrate and the like. In certain embodiments, the presence of DAMPs is able to enhance the efficiency of reprograming as a result of exposure to the reprograming factors.

“Aluminum compositions” as used herein refers to molecules containing elemental aluminum, aluminum salts, aluminum ions and/or aluminum covalently or ionically bonded to another element. In some embodiments, the term relates to aluminum salts, aluminum hydroxides, aluminum sulfates and aluminum phosphates.

“Aluminum” is a chemical element in the boron group with symbol Al and atomic number 13. It is a silvery white, soft, ductile metal. Aluminum is the third most abundant element (after oxygen and silicon), and the most abundant metal, in the Earth's crust. The majority of compounds, including all Al-containing minerals and all commercially significant aluminum compounds, feature aluminum in the oxidation state 3+. The coordination number of such compounds varies, but generally Al3+ is six-coordinate or tetracoordinate. Almost all compounds of aluminum (III) are colorless. Aluminum forms one stable oxide, known by its mineral name corundum. Sapphire and ruby are impure corundum contaminated with trace amounts of other metals. The two oxide-hydroxides, AlO(OH), are boehmite and diaspore. There are three trihydroxides: bayerite, gibbsite, and nordstrandite, which differ in their crystalline structure (polymorphs). Most are produced from ores by a variety of wet processes using acid and base. Heating the hydroxides leads to formation of corundum.

“Aluminum hydroxide” as referred to herein is Al(OH)₃, ATH, sometimes erroneously called hydrate of alumina, is found in nature as the mineral gibbsite (also known as hydrargillite) and its three, more rare polymorphs: bayerite, doyleite and nordstrandite. Freshly precipitated aluminum hydroxide forms gels, which is the basis for application of aluminum salts as flocculants in water purification. This gel crystallizes with time. Aluminum hydroxide gels can be dehydrated (e.g., using water-miscible non-aqueous solvents like ethanol) to form an amorphous aluminum hydroxide powder, which is readily soluble in acids. Aluminum hydroxide powder which has been heated to an elevated temperature under carefully controlled conditions is known as activated alumina and is used as a desiccant, an adsorbent, in gas purification, as a Claus catalyst support, water purification, and an adsorbent for the catalyst during the manufacture of polyethylene by the Sclairtech process. Gibbsite has a typical metal hydroxide structure with hydrogen bonds. It is built up of double layers of hydroxyl groups with aluminum ions occupying two-thirds of the octahedral holes between the two layers.

Aluminum hydroxide may be commercially manufactured by the Bayer process which involves dissolving bauxite in sodium hydroxide at temperatures up to 270° C. The remaining solids, which is a red mud, is separated and aluminum oxide is precipitated from the remaining solution. The aluminum oxide that is produced can be converted to aluminum hydroxide through reaction with water.

“Aluminum Phosphate” (AlPO₄) is a chemical compound whose anhydrous form is found in nature as the mineral berlinite. Many synthetic forms of anhydrous aluminum phosphate are also known. They have framework structures similar to zeolites and some are used as catalysts or molecular sieves. A hydrated form, AlPO₄.1.5H₂O is known. An aluminum phosphate gel is also commercially available. There are a large number of aluminum phosphate molecular sieves, generically known as ‘ALPOs’. They share the same chemical composition of AlPO₄ and have framework structures with microporous cavities and the frameworks are made up of alternating AlO₄ and PO₄ tetrahedra. The denser cavity-less crystalline AlPO₄ mineral, berlinite shares the same alternating AlO₄ and PO₄ tetrahedra. The aluminophosphate framework structures vary one from another in the orientation of the AlO₄ tetrahedra and PO₄ tetrahedra to form different sized cavities and in this respect they are similar to the aluminosilicate zeolites which differ in having electrically charged frameworks. A typical preparation of an aluminophosphate involves the hydrothermal reaction of phosphoric acid and aluminum in the form of hydroxide, an aluminum salt such as aluminum nitrate salt or alkoxide under controlled pH in the presence of organic amines. These organic molecules act as templates, (now termed structure directing agents to direct the growth of the porous framework).

“Aluminum sulfate” is a chemical compound with the formula Al₂(SO₄)₃. It is soluble in water and is mainly used as a flocculating agent in the purification of drinking water. Aluminum sulfate is sometimes referred to as a type of alum. Alums are a class of related compounds typified by AB(SO₄)₂.12H₂O. The anhydrous form occurs naturally as a rare mineral millosevichite, found e.g. in volcanic environments and on burning coal-mining waste dumps. Aluminum sulfate is rarely, if ever, encountered as the anhydrous salt. It forms a number of different hydrates, of which the hexadecahydrate Al₂(SO₄)₃.16H₂O and octadecahydrate Al₂(SO₄)₃.18H₂O are the most common. The heptadecahydrate, whose formula can be written as [Al(H₂O)₆]₂(SO₄)₃.5H2O, occurs naturally as the mineral alunogen.

The dose of a DAMP (e.g., an aluminum composition) that is effective in the methods of the invention is a dose that increases the efficiency of reprogramming of a cell or cell population, relative to the same method conducted in the absence of the DAMP. The term “reprogramming” as used herein means nuclear reprogramming of a somatic cell to a pluripotential cell (e.g., a fibroblast to an induced pluripotential cell) or nuclear reprogramming of a somatic cell to a substantially different somatic cell (e.g., a fibroblast to an endothelial cell), in vitro or in vivo. The latter process is also known as transd ifferentiation.

In certain embodiments, the cells being reprogramed are exposed to a concentration of DAMP such as an aluminum composition, having a concentration of about or at least or exactly 1, 10, 10² or 10³ times 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 181, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 nanograms, micrograms, milligrams or grams per ml of cell culture medium. In another embodiment, the cells are exposed to such a concentration for about or at least or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 181, 19, 20, 21, 22, 23, 24 minutes, hours or days before, after or during exposure of the somatic cells to reprograming factors.

The term “efficiency of reprogramming” may be used to refer to the ability of cells to give rise to iPS cell colonies when contacted with reprogramming factors. Somatic cells that demonstrate an enhanced efficiency of reprogramming to pluripotentiality will demonstrate an enhanced ability to give rise to iPSCs when contacted with reprogramming factors relative to a control. The term “efficiency of reprogramming” may also refer to the ability of somatic cells to be reprogrammed to a substantially different somatic cell type, a process known as transdifferentiation. The efficiency of reprogramming with the methods of the invention vary with the particular combination of somatic cells, method of introducing reprogramming factors, and method of culture following induction of reprogramming.

In certain embodiments, the presence of a DAMP results in about or at least or exactly 1, 10, 10² or 10³ times 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 181, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percentage increase in: 1) the expression level of one or more key pluripotency markers; or 2) the number of iPSCs formed, each in comparison to the same method for reprogramming but lacking the DAMP (i.e., a control).

Methods of Inducing Pluripotency In Vitro

A starting population of somatic cells is contacted with reprogramming factors, as defined above, in a combination and quantity sufficient to reprogram the cell to pluripotency prior to, concurrent with or following activation of the somatic cell with an effective dose of a DAMP. In one embodiment of the invention, the aluminum composition is aluminum hydroxide. Reprogramming factors may be provided to the somatic cells individually or as a single composition, that is, as a premixed composition, of reprogramming factors. In another embodiment, the starting population of somatic cells is peripheral blood mononuclear cells (PBMCs), cord blood mononuclear cells, or fibroblasts.

In some embodiments, the starting population of cells is contacted with an effective dose of a DAMP from a period of time from about 1 to about 18 days, e.g. from about 1 to about 5 days, and may be around 2 to 3 days.

The reprogramming factors may be added to the subject cells simultaneously or sequentially at different times, and may be added in combination with the DAMP. In some embodiments, a set of at least three purified reprogramming factors is added, e.g., an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4, c-myc, nanog or lin28 polypeptide. In some embodiments, a set of four purified reprogramming factors is provided to the cells e.g., an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide and a c-Myc polypeptide; or an Oct3/4 polypeptide, a Sox2 polypeptide, a 1in28 polypeptide and a nanog polypeptide.

Methods for introducing the reprogramming factors to somatic cells include providing a cell with purified protein factors or nucleic acids encoding them. In some embodiments, a reprogramming factor will comprise the polypeptide sequences of the reprogramming factor fused to a polypeptide permeant domain. A number of permeant domains are known in the art and may be used in the nuclear acting, non-integrating polypeptides of the present invention, including peptides, peptidomimetics, and non-peptide carriers. For example, a permeant peptide may be derived from the third alpha helix of Drosophila melanogaster transcription factor Antennapaedia, referred to as penetratin, which comprises the amino acid sequence RQIKIWFQNRRMKWKK (SEQ ID NO: 13). As another example, the permeant peptide comprises the HIV-1 tat basic region amino acid sequence, which may include, for example, amino acids 49-57 of naturally-occurring tat protein. Other permeant domains include poly-arginine motifs, for example, the region of amino acids 34-56 of HIV-1 rev protein, nona-arginine (SEQ ID NO: 14), octa-arginine (SEQ ID NO: 15), and the like. (See, for example, Futaki et al. (2003) Curr Protein Pept Sci. 2003 April; 4(2): 87-96; and Wender et al. (2000) Proc. Natl. Acad. Sci. U.S.A 2000 November 21; 97(24):13003-8; published U.S. Patent applications 20030220334; 20030083256; 20030032593; and 20030022831, herein specifically incorporated by reference for the teachings of translocation peptides and peptoids). The nona-arginine (R9) (SEQ ID NO: 14) sequence is one of the more efficient PTDs that have been characterized (Wender et al. 2000; Uemura et al. 2002).

In such embodiments, cells are incubated in the presence of a purified reprogramming factor for about 30 minutes to about 72 hours, e.g., 2 hours, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours 36 hours, 48 hours, 60 hours, 72 hours, or any other period from about 30 minutes to about 72 hours. Typically, the reprogramming factors are provided to the subject cells four times, and the cells are allowed to incubate with the reprogramming factors for 48 hours, after which time the media is replaced with fresh media and the cells are cultured further (See, for example, Zhou et al. (2009) Cell Stem Cells 4(5); 381-384). The reprogramming factors may be provided to the subject cells for about one to about 4 weeks, e.g. from about two to about 3 weeks.

The dose of reprogramming factors will vary with the nature of the cells, the factors, the culture conditions, etc. In some embodiments the dose will be from about 1 nM to about 1 μM for each factor, more usually from about 10 nM to about 500 nM, or around about 100 to 200 nM. In some embodiments, the cells are initially exposed to an aluminum composition during exposure to the reprogramming actors for at least about I day, at least about 2 days, at least about 4 days, at least about 6 days or one week, and may be exposed for the entire reprogramming process, or less. The dose will depend on the specific DAMP, but may be from about 1 ng/ml to about 1 μg/ml, from about 10 ng/ml to about 500 ng/ml. Two 16-24 hour incubations with the recombination factors may follow each provision, after which the media is replaced with fresh media and the cells are cultured further.

In some embodiments, a vector that does not integrate into the somatic cell genome is used. Many vectors useful for transferring exogenous genes into target mammalian cells are available. The vectors may be maintained episomally, e.g. as plasmids, virus-derived vectors such cytomegalovirus, adenovirus, etc. Vectors used for providing reprogramming factors to the subject cells as nucleic acids will typically comprise suitable promoters for driving the expression, that is, transcriptional activation, of the reprogramming factor nucleic acids. This may include ubiquitously acting promoters, for example, the CMV-beta-actin promoter, or inducible promoters, such as promoters that are active in particular cell populations or that respond to the presence of drugs such as tetracycline. By transcriptional activation, it is intended that transcription will be increased above basal levels in the target cell by at least or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 100 or 1000 fold.

Following introduction of reprogramming factors, the somatic cells may be maintained in a conventional culture medium comprising feeder layer cells, or may be cultured in the absence of feeder layers, i.e. lacking somatic cells other than those being induced to pluripotency. Feeder layer free cultures may utilize a protein coated surface, e.g. matrigel, etc. The somatic cells may also be maintained in suspension or attached to microcarriers.

iPSCs induced to become such by the methods of the invention may have an hESC-like morphology, growing as flat colonies with large nucleo-cytoplasmic ratios, defined borders and prominent nuclei. In addition, the iPSCs may express one or more key pluripotency markers known by one of ordinary skill in the art, including but not limited to Alkaline Phosphatase, SSEA3, SSEA4, Sox2, Oct3/4, Nanog, TRA160, TRA181, TDGF 1, Dnmt3b, FoxD3, GDF3, Cyp26al, TERT, and zfp42. In addition, the iPSCs are capable of forming teratomas. In addition, they are capable of forming or contributing to ectoderm, mesoderm, or endoderm tissues in a living organism.

Genes may be introduced into the somatic cells or the iPSCs derived therefrom for a variety of purposes, e.g. to replace genes having a loss of function mutation, provide marker genes, etc. Alternatively, vectors are introduced that express antisense mRNA or ribozymes, thereby blocking expression of an undesired gene. Other methods of gene therapy are the introduction of drug resistance genes to enable normal progenitor cells to have an advantage and be subject to selective pressure, for example the multiple drug resistance gene (MDR), or anti-apoptosis genes, such as bcl-2. Various techniques known in the art may be used to introduce nucleic acids into the target cells, e.g. electroporation, calcium precipitated DNA, fusion, transfection, lipofection, infection and the like, as discussed above. The particular manner in which the DNA is introduced is not critical to the practice of the invention.

The iPSCs produced by the above methods may be used for reconstituting or supplementing differentiating or differentiated cells in a recipient. The induced cells may be differentiated into cell-types of various lineages. Examples of differentiated cells include any differentiated cells from ectodermal (e.g., neurons and fibroblasts), mesodermal (e.g., cardiomyocytes), or endodermal (e.g., pancreatic cells) lineages. The differentiated cells may be one or more: pancreatic beta cells, neural stern cells, neurons (e.g., dopaminergic neurons), oligodendrocytes, oligodendrocyte progenitor cells, hepatocytes, hepatic stem cells, astrocytes, myocytes, hematopoietic cells, or cardiomyocytes.

There are numerous methods of differentiating the induced cells into a more specialized cell type. Methods of differentiating induced cells may be similar to those used to differentiate stern cells, particularly ES cells, MSCs, MAPCs, MIAMI, hematopoietic stem cells (HSCs). In some cases, the differentiation occurs ex vivo; in some cases the differentiation occurs in vivo.

The induced cells, or cells differentiated from the induced cells, may be used as a therapy to treat disease (e.g., a genetic defect). The therapy may be directed at treating the cause of the disease; or alternatively, the therapy may be to treat the effects of the disease or condition. The induced cells may be transferred to, or close to, an injured site in a subject; or the cells can be introduced to the subject in a manner allowing the cells to migrate, or home, to the injured site. The transferred cells may advantageously replace the damaged or injured cells and allow improvement in the overall condition of the subject. In some instances, the transferred cells may stimulate tissue regeneration or repair.

The transferred cells may be cells differentiated from induced cells. The transferred cells also may be multipotent stem cells differentiated from the induced cells. In some cases, the transferred cells may be induced cells that have not been differentiated.

The number of administrations of treatment to a subject may vary. Introducing the induced and/or differentiated cells into the subject may be a one-time event; but in certain situations, such treatment may elicit improvement for a limited period of time and require an on-going series of repeated treatments. In other situations, multiple administrations of the cells may be required before an effect is observed. The exact protocols depend upon the disease or condition, the stage of the disease and parameters of the individual subject being treated.

The cells may be introduced to the subject via any of the following routes: parenteral, intravenous, intraarterial, intramuscular, subcutaneous, transdermal, intratracheal, intraperitoneal, or into spinal fluid.

The iPSCs may be administered in any physiologically acceptable medium. They may be provided alone or with a suitable substrate or matrix, e.g. to support their growth and/or organization in the tissue to which they are being transplanted. Usually, at least 1×10⁵ cells will be administered, preferably 1×10⁶ or more. The cells may be introduced by injection, catheter, or the like. The cells may be frozen at liquid nitrogen temperatures and stored for long periods of time, being capable of use on thawing. If frozen, the cells will usually be stored in a 10% DMSO, 50% FCS, 40% RPMI 1640 medium. Once thawed, the cells may be expanded by use of growth factors and/or stromal cells associated with progenitor cell proliferation and differentiation.

Kits may be provided, where the kit comprises an effective dose of a DAMP such as an aluminum composition. In some embodiments the aluminum composition is a aluminum hydroxide. The kit may further comprise one or more reprogramming factors, e.g. in the form of proteins fused to a permeant domain.

“Treating” or “treatment” is referred to herein as administration of a substance to a subject with the purpose to cure, alleviate, relieve, remedy, prevent, or ameliorate a disorder, symptoms of the disorder, a disease state secondary to the disorder, or predisposition toward the disorder. An “effective amount” is an amount of the substance that is capable of producing a medically desirable result as delineated herein in a treated subject. The medically desirable result may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).

“Disease amenable to treatment with stem cell therapy” as referred to herein means any procedures, conditions, disorders, ailments and/or illnesses which can be treated by the administration of stem cells such as iPSCs. Such diseases include but are not limited to bone marrow, skin, heart, and corneal transplantation, graft versus host disease, hepatic and renal failure, lung injury, rheumatoid arthritis, treatment of autoimmune diseases such as Crohn's disease, ulcerative colitis, multiple sclerosis, lupus and diabetes; prevention of allograft rejection, neurological disorders and cardiovascular medicine; as well as Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Burkitt's lymphoma, Chronic myeloid leukemia (CML), Juvenile myelomonocytic leukemia (JMML), Non-Hodgkin's lymphoma Hodgkin's lymphoma, Lymphomatoid granulomatosis, Myelodysplastic syndrome (MDS), Chronic myelomonocytic leukemia (CMML), Bone Marrow Failure Syndromes, Amegakaryocytic thrombocytopenia, Autoimmune neutropenia (severe), Congenital dyserythropoietic anemia, Cyclic neutropenia, Diamond-Blackfan anemia, Evan's syndrome, Fanconi anemia, Glanzmann's disease, Juvenile dermatomyositis, Kostmann's syndrome, Red cell aplasia, Schwachman syndrome, Severe aplastic anemia, Congenital sideroblastic anemia, Thrombocytopenia with absent radius (TAR syndrome), Dyskeratosis congenital, Blood Disorders, Sickle-cell anemia (hemoglobin SS), HbSC disease, Sickle βo Thalassemia, α-thalassemia major (hydrops fetalis), β-thalassemia major (Cooley's anemia), β-thalassemia intermedia, E-βo thalassemia, E-β+ thalassemia, Metabolic Disorders, Adrenoleukodystrophy Gaucher's disease (infantile), Metachromatic leukodystrophy, Krabbe disease (globoid cell leukodystrophy), Gunther disease, Hermansky-Pudlak syndrome, Hurler syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo syndrome, Maroteaux-Lamy syndrome, Mucolipidosis Type II, III, Alpha mannosidosis, Niemann Pick Syndrome, type A and B, Sandhoff Syndrome, Tay-Sachs Disease, Batten disease (inherited neuronal ceroid lipofuscinosis), Lesch-Nyhan disease, Immunodeficiencies, Ataxia telangiectasia, Chronic granulomatous disease, DiGeorge syndrome, IKK gamma deficiency, Immune dysregulation polyendocrineopathy, X-linked Mucolipidosis, Type II, Myelokathexis X-linked immunodeficiency, Severe combined immunodeficiency, Adenosine deaminase deficiency, Wiskott-Aldrich syndrome, X-linked agammaglobulinemia, X-linked lymphoproliferative disease, Omenn's syndrome, Reticular dysplasia, Thymic dysplasia, Leukocyte adhesion deficiency, Other Osteopetros is, Langerhans cell histiocytosis, Hemophagocytic lymphohistiocytosis, Acute & Chronic Kidney Disease, Alzheimer's disease, Anti-Aging, Arthritis, Asthma, Cardiac Stem Cell Therapy, Cerebral Infarction (Stroke), Cerebral Palsy (Stroke), Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure, Diabetes Mellitus (Type I & II), Fibromyalgia, Immune Deficiencies, Ischemic Heart Disease, Lupus, Multiple Sclerosis, Myocardial Infarction, Osteoarthritis, Osteoporosis, Parkinson's Disease, Peripheral Arterial Disease, Rheumatoid Arthritis, Stem Cell Therapy in Plastic Surgery, Traumatic Brain Injury and Neurological Diseases.

“Patient” as used herein refers to a mammalian subject diagnosed with or suspected of having or developing a disease amenable to stem cell therapy, e.g., cardiovascular disease. Exemplary patients may be humans, apes, dogs, pigs, cattle, cats, horses, goats, sheep, rodents and other mammalians that can benefit from stem cell therapies.

“Administering” is referred to herein as providing the iPSCs of the invention to a patient. By way of example and not limitation, composition administration, e.g., injection, may be performed by intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, or intramuscular (i.m.) injection. One or more such routes may be employed. Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time. Alternatively, or concurrently, administration may be by the oral route. Additionally, administration may also be by surgical deposition of a bolus or pellet of cells, or positioning of a medical device, e.g., a stent, loaded with cells. Preferably, the compositions of the invention are administered at the site of disease, e.g. at the site or near (e.g., about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50 millimeters from) the site of a disease lesion (e.g., vascular stenosis/blockage, necrotic tissue or site of gangrenous infection).

“A patient in need thereof” is referred to herein as a patient diagnosed with or suspected of having a disease amendable to stem cell therapy.

EXAMPLE

Reprogramming of human cord blood CD34+ cells or peripheral blood mononuclear cells with episomal plasmids and aluminum hydroxide under feeder free conditions.

This procedure generates human induced pluripotent stem cells (iPSCs) by reprogramming human cord blood CD34+ cells or PBMCs using episomal plasmids, Lonza 4D-Nucleofector™ system, Lonza #7 PSC medium and a human vitronectin matrix.

Materials used include: Human cord blood CD34⁺ cells (Lonza, Cat. No. 2C-101) or Human peripheral blood mononuclear cells (Lonza, Cat. No. CC-2702); Blood Cell Medium containing serum free basal medium, 50% IMDM (Invitrogen Cat No. 12440-053), 50% Ham's F12 (Invitrogen cat No. 11765054), 1× Chemically defined lipid concentration (Invitrogen Cat No. 11905-031), lx Insulin-Transferrin-Selenium-X (ITS-X) (Invitrogen Cat No. 51500), 50ug/mL Ascorbic acid (Sigma-Aldrich Cat No. 49752), 5 mg/mL Bovine Albumin Fraction V solution (Invitrogen Cat No. 15260-037), 2 mM GlutaMaxTM-I (Invitrogen Cat No. 35050) as well as cord blood-specific growth factors including 100 ng/mL Recombinant human SCF (Peprotech Cat No. AF-300-07), 100 ng/mL Recombinant human Flt3-ligand (Peprotech Cat No. AF-300-19), 20 ng/mL Recombinant human TPO (Peprotech Cat No. 300-18), and 10 ng/mL Recombinant human IL-3 (Peprotech Cat No. 200-03) as well as PBMC specific growth factors such as 200 μM 1-thioglycerol (Sigma #M6145), 100 μg/mL Holo-transferrin (R&D Systems #2914-HT), 1 μM Dexamethasone (Sigma #D1756), 100 ng/mL (PeproTech #300-07), 2U/mL EPO (R&D Systems #287-TC-500), 10 ng/mL IL-3 (PeproTech #200-03), and Alro 40 ng/mL IGF-1 (Peprotech #100-11). Also used are cGMP-grade pEB-C5 and pEB-Tg plasmids; alternatively pCE-OCT3/4, pCE-hSK, pCE-hUL, pCE-p53mDD, pCE-EBNA1, Alhydrogel 2% (Invitrogen vac-alu-50), Lonza #7 Pluripotent Stem Cell (PSC) medium, 0.4% Trypan Blue solution (Invitrogen cat No 15250061), 1×DPBS (Lonza Cat No. 17-512F), 1×DPBS++ (Lonza cat No 17-513F) and a P3 Primary Cell 4D-Nucleofector™ X Kit L (Lonza Cat No. V4XP-3012).

The Equipment used includes a Lonza 4D-Nucleofector™ system (Lonza Cat No. AAF-1001B, AAF-1001X), Humidified incubator at 37° C.±2° C. with 5% CO2±2%, 3.8% O2, Biohazard trash receptacle, Tissue culture hood, Hemocytometer, Microscope, 37° C. water bath, Centrifuge capable of 200×g with rotors for 15 mL tubes, Costar Stripette Paper-Wrapped Disposable Polystyrene Serological Pipets 10 mL (Thermofisher Cat No. 07-200-574), Costar Stripette Paper-Wrapped Disposable Polystyrene Serological Pipets 10 mL (Thermofisher Cat No. 07-200-573), Drummond Portable Pipet-Aid Filler/Dispensers XP (Thermofisher Cat No. 13-681-15E), Sterile Costar Microcentrifuge Tubes RNase free certified 1.7 mL Natural (ThermoFisher Cat No. 07-200-534), Sterile 1000uL filter micropipette tip (Rainin Cat No. RT-1000F), Sterile 200 μL filter micropipette tip (Rainin Cat No. RT-200F), Sterile 20 μL filter micropipette tip (Rainin Cat No. RT-20F), Sterile 10 μL filter micropipette tip (Rainin Cat No. RT-10GF), Pipet-Lite XLS 1000 μL micropipette (Rainin Cat No. SL-STARTXLS), Pipet-Lite XLS 200 μL micropipette (Rainin Cat No. SL-STARTXLS), Pipet-Lite XLS 20 μL micropipette (Rainin Cat No. SL-STARTXLS), Pipet-Lite XLS with RFID 0.1-2 μL micropipette (Rainin Cat No. SL-2XLS), Corning 12-well tissue culture plate (Corning Cat No. 3513), 6-well tissue culture plate (ThermoFisher Cat No. 08-772-1B), Falcon 15 mL conical centrifuge tube (ThermoFisher Cat No. 14-959-70C).

On day 0, the procedure includes Cell Nucleofection as follows: Coat tissue culture plates (9.6cm²/well) with lmL vitronectin at a concentration of 10 μg/mL. Allow coating to incubate 1 hour. Ensure Alhydrogel is evenly suspended by vortexing. Combine Alhydrogel and SFM at a ratio of 3 μL for each mL SFM. For each transfection sample, transfer 2 mL of SFM into 1 well of a 6-well plate. Put plate in 37° C. humidified incubator to pre-warm the medium. Collect human blood cells in a Falcon 15 mL conical tube. Take 10 μL of cell suspension and mix well with 10 μL of Trypan Blue. Count viable cells using a hemocytometer under a microscope. For each transfection sample, place 10⁶ viable cells in a new 15 mL tube and centrifuge cells at 200 g for five (5) minutes. Remove supernatant. Freeze cells quickly on dry ice and store at −80° C. for future STR analysis. Combine 82 μL P3 solution and 18 μL supplement from P3 Primary Cell 4D-Nucleofector™ X Kit L in a sterile microcentrifuge tube. Add pEB-C5: pEB-Tg or pCE-OCT3/4: pCE-hSK: pCE-hUL: pCE-p53mDD: pCE-EBNA1 plasmids at ratios of 8:2 or 0.63: 0.63: 0.63: 0.63: 0.5 μg respectively and mix well. Resuspend cells with pre-mixed Nucleofection™ Solution previously prepared. Mix well with micropipette and transfer to a Nucleofection™ cuvette (provided with kit). Nucleofect cells using 4D-Nucleofector™ using program EO-100. After Nucleofection, take 0.5 mL pre-warmed SFM and add into the cuvette using micropipette in the tissue culture hood. Then use a transfer pipet provided with the Nucleofection™ kit to transfer the cells to the pre-warmed SFM in 1 well of 6-well plate. Place plate into a humidified incubator.

On day 2 the procedure is as follows: Dilute 40 μL of 250 μg/mL vitronectin into 1 mL of 1×DPBS⁺⁺ and add into 1 well of 6-well plate. Coat the plate in an incubator for three (3) hours. Transfer Nucleofected CD34+ cells into one 15 mL tube and centrifuge cells at 200 g for five (5) minutes. Remove the medium and resuspend cells in 2 mL Lonza #7 medium. Add 0.2 uL of 10 uM A8301 (f.c. 1 μM) into the cell suspension. Aspirate off vitronectin from the well and seed cells into it. Put the plate into the incubator.

On days 2 and 4 the procedure involves the following steps: Every other day add 1.5 mL L7 until well volume exceeds 5 mL.

On day 6 the procedure is as follows: When well volume exceeds 6 mL, aspirate the supernatant leaving behind an approximate volume of 1 mL medium. Gently handle culture so as not to disturb the cells covering the bottom of the well. Add 1.5 mL Lonza #7 PSC medium.

Repeat the procedures from Days 2, 4 and 6 until colonies appear roughly between days 14 to 18.

On day 16, prepare 24-well vitronectin-coated plates.

On days 18 to 20 the procedure involves colony picking steps as follows: Aspirate vitronectin coating from 12-well plate. To empty wells, add 250 μL L7 Medium. Under phase microscope, mark colonies for picking based on morphology. Conduct the following steps one colony at a time. Under dissecting scope, scrape colonies from the surface of the well with a micropipette tip. Draw colony into micropipette tip into roughly 30 μL of volume. Transfer colony into 24-well plate. After colonies have been collected, place 24-well plate into a humidified, 5% CO₂, 20% O₂, 37° C. incubator.

Unless defined otherwise, all technical and scientific terms and any acronyms used herein have the same meanings as commonly understood by one of ordinary skill in the art in the field of this invention. Although any compositions, methods, kits, and means for communicating information similar or equivalent to those described herein can be used to practice this invention, the preferred compositions, methods, kits, and means for communicating information are described herein.

All references cited herein are incorporated herein by reference to the full extent allowed by law. The discussion of those references is intended merely to summarize the assertions made by their authors. No admission is made that any reference (or a portion of any reference) is relevant prior art. Applicants reserve the right to challenge the accuracy and pertinence of any cited reference. 

What is claimed is:
 1. A method of enhancing nuclear reprogramming of a mammalian somatic cell, the method comprising: contacting a population of mammalian somatic cells stem cells with (a) an effective dose of a Damage-associated molecular pattern molecule (DAMP); and (b) a cocktail of reprogramming factors; for a period of time sufficient to reprogram the mammalian somatic cells to a desired cell type of interest.
 2. The method of claim 1, wherein the DAMP molecule is an aluminum composition.
 3. The method of claim 2, wherein the aluminum composition and reprogramming factors are provided sequentially or simultaneously.
 4. The method of any one of claims 2-3 wherein the aluminum composition is selected from the group consisting of aluminum hydroxide, aluminum phosphate and aluminum sulfate.
 5. The method of claim 4, wherein the aluminum composition is aluminum hydroxide.
 6. The method of claim 5, wherein the effective dose of aluminum hydroxide is about or at least 40-80 micrograms/ml.
 7. The method of claim 6, wherein the effective dose of the aluminum hydroxide is at least or about 60 micrograms/ml.
 8. The method of claim 4, wherein the aluminum composition is aluminum phosphate.
 9. The method of claim 4, wherein the aluminum composition is aluminum sulfate.
 10. The method of claim 1, wherein the mammalian somatic cells are human cells.
 11. The method of claim 2, wherein the cocktail of reprogramming factors comprises the use of nucleic acids encoding Oct4, Sox2, Lin28, and Nanog, or corresponding cell permeant peptides of the same, and the cells are reprogrammed to pluripotency.
 12. The method of claim 2, wherein the cocktail of reprogramming factors comprises the use of nucleic acids encoding Oct4, Sox2, c-Myc, and KLF4, or corresponding cell permeant peptides of the same, and the cells are reprogrammed to pluripotency.
 13. The method of claim 1, wherein the mammalian somatic cell type is peripheral blood monoculear cell (PBMC), cord blood mononuclear cells, or fibroblasts.
 14. The method of claim 1, wherein the reprogramming factors are provided as cell permeant proteins.
 15. The method of claim 1, wherein the reprogramming factors are provided as nucleic acids encoding the proteins.
 16. The method of claim 1, wherein the desired cell type of interest is an induced pluripotent stem (iPS) cell.
 17. The method of claim 1, resulting in a nuclear reprogramming efficiency wherein the nuclear reprogramming efficiency is greater than if the method was carried out without DAMP.
 18. The method of claim 17 wherein the nuclear reprogramming efficiency is about 1 to about 5 fold greater with respect to the expression of at least one key pluripotency marker.
 19. The method of claim 17 wherein the nuclear reprogramming efficiency is about 1 to about 5 fold greater with respect to an amount of the desired cell type of interest produced.
 20. A population of induced mammalian pluripotent stem cells produced by any of the methods of claims 1-19.
 21. The population of induced pluripotent stem cells of claim 20, wherein the induced pluripotent stem (iPS) cell are human cells.
 22. A kit for practicing the method of claim
 1. 23. A therapeutic composition comprising an aluminum composition and one or more cell permeant peptides and/or nucleic acids encoding such peptides and/or small molecules, for administration in vivo, for therapeutic modulation of cell and/or tissue phenotype.
 24. A method of treating a patient in need thereof by administering to the patient a therapeutically effective amount of the therapeutic composition of claim
 23. 25. A therapeutic composition comprising the cells of claim 21 in combination with a pharmaceutically acceptable carrier. 